Discover CME, tools, and guideline-focused education to improve your knowledge - and patient outcomes.
Chairperson’s Perspective: Optimizing Perioperative Therapy in Early-Stage NSCLC: A Multidisciplinary Approach
Heather Wakelee, MD, FASCO
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
John M. Kirkwood, MD
Sapna Patel, MD
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
Innovations in Oncology Learning Center: From Guidelines to Practice: Melanoma
Paolo A. Ascierto, MD
Hussein Tawbi, MD, PhD
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
Kevin Kalinsky MD, MS
Komal Jhaveri, MD, FACP
Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Community Clinic: Translating Data Into Action ─ Practical Strategies for Optimizing First-Line RCC Management
Robert J. Motzer, MD
Elizabeth R. Plimack, MD, MS, FASCO
Advancing Myasthenia Gravis (MG) Treatment Through Guideline Updates and Emerging Therapies
October 30, 2025
San Francisco, California
Chairperson's Perspective: Innovative Approaches to IBS-C: Personalized Treatment for Better Outcomes
Darren Brenner, MD
Expert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer
Neal Shore, MD, FACS
Sarah Psutka, MD, MS
Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
HER2 in Bladder Cancer: Breaking Through the Molecular Frontier
Vadim S. Koshkin, MD
Non-CF Bronchiectasis: How Radiologists Can Drive Better Outcomes
Robert D. Suh, MD
Lea Azour, MD
Ashwin Basavaraj, MD
SunRISe-1: 1-Year Durability and Patient-Reported Outcomes Results
Treatment Advances in Generalized Myasthenia Gravis: A Pathophysiology-Driven Framework Leveraging FcRn Therapeutics
Vera Bril, MD
Neelam Goyal, MD
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
What’s New In Glaucoma?
Paul Petrakos, DO, MS
Justin Schweitzer, OD, FAAO
I. Paul Singh, MD
Sarah H. Van Tassel, MD
New Frontiers in MG: How FcRn Antagonists Are Changing MG Therapy
Nicholas J. Silvestri, MD
Managing Side Effects in FcRn Therapy: Best Practices for gMG
Treatment Advances in Generalized Myasthenia Gravis: Addressing the Nuances of its Underlying Immunopathology
Hans Katzberg, MD
Treatment Advances in Generalized Myasthenia Gravis: Clinical and Laboratory Criteria for Diagnosis and Optimal Treatment Selection
Jonathan Strober, MD
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.